Mitochondrial peptides represent one of the most exciting frontiers in longevity medicine. MOTS-c and SS-31 (Elamipretide) are the two most prominent peptides targeting mitochondrial function, but they approach the problem from entirely different angles.
How They Work
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c) is a 16-amino-acid peptide encoded within the mitochondrial genome. It was discovered in 2015 at USC and functions as a retrograde signal — a message sent from mitochondria back to the nucleus. MOTS-c activates AMPK (AMP-activated protein kinase), the master metabolic sensor, which in turn enhances glucose uptake, promotes fatty acid oxidation, and improves insulin sensitivity. Exercise increases circulating MOTS-c levels, leading researchers to describe it as an "exercise mimetic" at the molecular level. MOTS-c levels decline with age, which may contribute to age-related metabolic dysfunction.
SS-31 (D-Arg-Dmt-Lys-Phe-NH2), also known as Elamipretide, is a synthetic cell-permeable tetrapeptide that targets the inner mitochondrial membrane directly. It binds to cardiolipin, a phospholipid critical for the structural integrity and function of electron transport chain (ETC) complexes. By stabilizing cardiolipin, SS-31 optimizes electron transfer, reduces electron leak and reactive oxygen species (ROS) production, and restores ATP synthesis efficiency. It was developed by Stealth BioTherapeutics and has progressed through clinical trials for multiple mitochondrial diseases.
What the Research Shows
MOTS-c research demonstrates powerful metabolic effects in preclinical models. In mice, it prevents diet-induced obesity, improves insulin sensitivity, and enhances physical performance in aging animals. Observational human studies show that circulating MOTS-c levels decrease with age and are lower in individuals with obesity and metabolic syndrome. While the preclinical data is compelling, human therapeutic trials are still in early stages.
SS-31 has more advanced clinical data. The TAZPOWER Phase 2 trial in Barth syndrome (a genetic mitochondrial disease) showed improvements in cardiac and skeletal muscle function. Additional clinical trials have evaluated SS-31 in heart failure, age-related macular degeneration, and renal injury. The peptide has achieved FDA approval for Barth syndrome (as Stegazo/Elamipretide), providing validated human safety and efficacy data.
Side Effects and Tolerability
MOTS-c has limited formal safety data in humans. Anecdotal reports suggest it is well tolerated, with injection site reactions and occasional mild nausea being the most common complaints. Long-term safety in humans remains unknown.
SS-31 safety is well-characterized through clinical trials. The most common side effects are injection site reactions (pain, redness). Some patients in trials reported headache and nausea. No serious safety signals have emerged, and the peptide has demonstrated a favorable risk-benefit profile across multiple disease states.
How to Choose
Choose MOTS-c if: your primary goal is metabolic optimization — improving insulin sensitivity, enhancing fat oxidation, supporting exercise performance, or addressing age-related metabolic decline. MOTS-c is the mitochondrial peptide most aligned with metabolic health and body composition goals.
Choose SS-31 if: your primary goal is direct mitochondrial protection — you have or suspect mitochondrial dysfunction, you want to reduce oxidative stress at the ETC level, or you are targeting age-related organ decline (cardiac, renal, retinal) where mitochondrial membrane integrity is a key driver. SS-31 has the stronger clinical evidence and regulatory backing.
Consider both if: you want comprehensive mitochondrial support addressing both metabolic signaling (MOTS-c) and structural membrane integrity (SS-31). This is a theoretical framework — combination data does not yet exist.